JY
CAI

Jeff Yass’s Caris Life Sciences CAI Stock Holding History

Jeff Yass’s Portfolio CAI Stock Details CAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.72M Buy
208,700
+45,500
+28% +$814K ﹤0.01% 5194
2026
Q1 		$2.92M Buy
163,200
+45,300
+38% +$990K ﹤0.01% 5320
2025
Q4 		$3.18M Sell
117,900
-27,500
-19% -$775K ﹤0.01% 4781
2025
Q3 		$4.4M Buy
+145,400
New +$4.64M ﹤0.01% 4284

Other funds holding CAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JHWEPV
J. H. Whitney Equity Partners VI New Canaan, Connecticut $201M AUM
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Jeff Yass's CAI Position: Q2 2026 in Review

Jeff Yass increased its Caris Life Sciences (CAI) stake by 285% in Q2 2026, buying an estimated $2.71M and bringing the position to 204,432 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5230.

Jeff Yass first reported a position in CAI in Q3 2025 and has held it in 3 quarters since. 246 funds tracked by Wall St. Rank hold CAI as of Q2 2026.

  • Jeff Yass held 204,432 shares of Caris Life Sciences worth $3.64M as of Q2 2026.
  • Jeff Yass bought 151,366 Caris Life Sciences shares in Q2 2026, an estimated $2.71M.
  • Caris Life Sciences made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #5230 holding.
  • Jeff Yass first reported a position in Caris Life Sciences in Q3 2025 and has held it in 3 quarters since.
  • 246 funds tracked by Wall St. Rank held Caris Life Sciences as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.